Investors & Media

Welcome to the Investor Relations and Public Relations division of Medigene AG. This is where you will find current information on a variety of subjects, including Medigene AG shares, company news, financial reports and key figures.

Latest News

Medigene's PD1-41BB switch receptor improves TCR-T cell functionality against solid tumors


Medigene extends cash reach into the first quarter of 2023


Medigene provides Q2 update and 6M report 2020


The Medigene Share

The Medigene share MDG1 (ISIN:DE000A1X3W00 ) is listed at the Frankfurt Stock Exchange since June 2000. 

show medigene share


26 - 28 Oct 2021

Neoantigen-based Therapies US Summit

10 - 14 Nov 2021

SITC 2021

11 Nov 2021

Quarterly Statement Q3 2021

16 - 18 Nov 2021

Cell Immunotherapies for Solid Tumors Summit

16 - 18 Nov 2021

12th Annual Jefferies Global Healthcare Conference

05 - 07 Jan 2022

LifeSci’s Virtual Corporate Access Event

22 - 24 Feb 2022

Next Generation CAR-TCR Summit

23 Mar 2022

Annual Report 2021

04 - 06 May 2022

Advanced Therapies

Corporate Governance

Good corporate governance is the basis of our decision-making and monitoring processes. It stands for responsible and value-based leadership and control of the Company for long-term success, goal-oriented and efficient cooperation between the Executive Board and Supervisory Board, respect for the interests of our shareholders and employees, consistently transparent and responsible corporate decisions and an appropriate risk management system.

read more

press photos

Laboratory work

DownLoad (9 MB)

Laboratory work (6)

Cell culture work

DownLoad (4 MB)

Laboratory work (7)

Cell sorting

DownLoad (353 KB)

Contact person

Dr. Anna Niedl
Vice President Investor Relations & Corporate Communications
Phone: +49 89 2000 3333 01
Fax: +49 89 2000 33 2920